Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1339970 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.48Day −2.23%Mkt cap $47M1Y −90.8%Off 52W high −92.6%Vol (1Y) 139.0%
Daily closing price, split-adjusted to the current basis; 2.1y shown of 535 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.4% of sh out |
| Days to cover4.3d |
| 13F net flow (QoQ)+1.29% |
| Top-10 13F concentration85.7% |
| Next report (est.)2026-08-15 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$190,000 |
| Earnings (TTM)-$70.0M |
| ROE−107.8% |
| Net margin−39009.5% |
| ROIC−106.4% |
| Sales growth 3Y−73.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−38.3% |
| 1Y−90.8% |
| Since incept. (ann.)−46.1% |
Total return through 2026-07-29 · series begins 2024-06-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)139.0% |
| Ann. volatility (3Y)112.9% |
| Sharpe (1Y)−0.71 |
| Sharpe (3Y)0.26 |
| Max drawdown (1Y)−93.6% |
| Max drawdown (3Y)−94.0% |
| Beta (3Y vs SPY)0.27 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 14.7M | $11M | 15.00% | +0.1% |
| FEDERATED HERMES, INC. | 10.5M | $8M | 10.72% | +0.0% |
| BlackRock, Inc. | 6.4M | $5M | 6.57% | −1.6% |
| UBS Group AG | 3.9M | $3M | 3.94% | +137.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8M | $3M | 3.89% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4M | $2M | 2.43% | +4.5% |
| STATE STREET CORP | 1.8M | $1M | 1.79% | +1.7% |
| GSA CAPITAL PARTNERS LLP | 1.7M | $1M | 1.72% | −36.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.11 | — | — | — |
| 2025-12-31 | 2026-03-05 | — | — | $0 | — |
| 2025-09-30 | 2025-11-06 | −$0.26 | — | $190,000 | — |
| 2025-06-30 | 2025-08-07 | −$0.22 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-15 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Collaboration Revenue 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
